ReviewJournal of thoracic disease2022
Oligoprogression in non-small cell lung cancer: a narrative review.
Review in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- First-line osimertinib in advancedESMO real world data and digital oncology · 2026Article
- Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).Clinical & experimental metastasis · 2026Article
- Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with AdvancedCancers · 2026Article
- Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.International journal of molecular sciences · 2026Review
- Article
- Article
- The Progression Patterns and Subsequent Treatments of First-Line Immunotherapy in Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Thoracic cancer · 2025Article
- Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study.International journal of molecular sciences · 2025Article
- Insights on Oligometastatic Non-Small-Cell Lung Cancer.Cancers · 2025Review
- Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.Journal for immunotherapy of cancer · 2025Article
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.The oncologist · 2025Article
- External validation of a genomic signature for oligometastatic non-small cell lung cancer.Journal of radiosurgery and SBRT · 2025Article
- The Use of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer Treatment-Literature Review.Biomedicines · 2024Review
- Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Scientific reports · 2024Article
- Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report.Oncology letters · 2024Article
- Paraneoplastic Diarrhea From Medullary Thyroid Carcinoma Resolved With Yttrium-90 Radioembolization of Liver Metastases.JCEM case reports · 2024Article
- Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.Translational lung cancer research · 2024Article
- Addressing the unmet need in NSCLC progression with advances in second-line therapeutics.Exploration of targeted anti-tumor therapy · 2024Review
- Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers and is the most common non-cutaneous cancer world-wide. In NSCLC, oligometastatic and oligoprogressive disease (OPD) have been recognized as separate entities within the realm of metastatic disease and are emerging concepts in the context of targeted systemic therapies. Our objectives are to discuss the current literature regarding the evolving definitions of OPD in the context of oligometastatic disease (OMD) for NSCLC. Further, to discuss current and future clinical trials that have shaped our local approach with stereotactic body radiation therapy (SBRT)/stereotactic ablative radiotherapy (SABR). Methods: Literature on OPD in NSCLC and local ablative therapy (LAT) including SBRT/SABR and stereotactic radiosurgery (SRS) was reviewed. Key Content and Findings: Oligoprogression is defined as limited (usually 3-5) metastatic areas progressing while on/off systemic therapy in the background of oligometastatic or polymetastatic disease. Prognosis in OPD with treatment (such as LAT and systemic therapy) may be more favorable. Outcomes for patients progressing on tyrosine kinase inhibitors (TKIs) with molecular mutations [such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)] who receive LAT are promising. Conclusions: Patients presenting with NSCLC metastasis with progression at a limited number of sites on/off a given line of systemic therapy may have favorable outcomes with aggressive LAT, which includes SBRT/SABR/SRS. Further studies need to be completed to further optimize treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.